Goldman Sachs Trims PT on Hologic (HOLX) After Q1, Keeps 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hologic, Inc. (HOLX) Reports In-Line Q1 EPS; Reaffirms
February 4, 2013 4:04 PM ESTHologic, Inc. (NASDAQ: HOLX) reported Q1 EPS of $0.38, in-line with the analyst estimate of $0.38. Revenue for the quarter came in at $631.4 million versus the consensus estimate of $646.52 million.
Hologic, Inc. sees FY2013 revenue of $2.61-2.64 billion, versus the consensus of $2.64 billion. sees FY2013 EPS of... More
